Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

This study is testing a combination of two drugs — zanubrutinib (a targeted cancer pill) and rituximab (an IV infusion) — for treating a rare and life-threatening condition called hemophagocytic lymphohistiocytosis (HLH) that occurs in patients with B-cell lymphoma. HLH is a severe immune overreaction that can be triggered by lymphoma. **You may be eligible if...** - You meet the standard diagnostic criteria for HLH - Your HLH is associated with a confirmed or strongly suspected B-cell lymphoma - You are between 14 and 80 years old - You are HIV-negative - Your kidney function and other labs are within acceptable ranges **You may NOT be eligible if...** - You have HLH from a cause other than B-cell lymphoma - You are HIV-positive - You have severe kidney or liver dysfunction - Your expected survival is less than one month - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.